Peptide ligands can be designed to target receptors overexpressed in tumor tissue (e.g., luteinizing hormone–releasing hormone (LHRH) receptor, integrin αvβ3, epidermal growth factor receptor [EGFR]), angiogenesis markers, or BBB receptors [157]. The gene discussed is EGFR; the disease is neoplasm.